Senior Director, Clinical & Scientific Affairs; Director, Guideline Development at @AMPath. MBA, PhD, HCLD(ABB). Tweets are my own; RTs ≠ endorsements
Joined April 2014
- Tweets2.7K
- Following1K
- Followers867
- Likes4.2K
Robyn Temple-Smolkin retweeted
🔥 NGS isn’t underused due to lack of data. It’s underused because reports are HARD to use.
▫️@AMPath @Pathologists consensus: Only 1/17 NSCLC reports were oncologist-friendly.
▫️The fix: Standardized, guideline-aligned reporting.
🔗 sciencedirect.com/science/ar…
Today's the day! We're now accepting abstracts for the AMP 2025 Annual Meeting & Expo (#AMPath2025) in Boston in November.
Submit by June 30 to be considered for a platform and/or poster presentation.
Here's the info you need: amp25.amp.org/abstract-poste…
Robyn Temple-Smolkin retweeted
🚨 Big news: The U.S. District Court has ruled in our favor, thwarting the FDA’s attempt to impose excessive regulations on laboratory-developed testing procedures (LDTs). This is a win for labs, patients and innovation! Ruling and opinion: amp.org/advocacy/amp-v-fda/
Robyn Temple-Smolkin retweeted
Today's the last day to secure early-bird pricing on our live online Molecular Genetic Pathology Review Course in May! This course will include lectures, case studies, live Q&A sessions and in-depth discussions. Learn more and register: amp.org/events/molecular-gen…
Robyn Temple-Smolkin retweeted
We're at @TheUSCAP's annual meeting this weekend! Swing by booth 1004 to meet our membership manager, Jocelyn Friedrich; get your hands on some "Molecular in My Pocket" reference cards; and find out what being a member of @AMPath can mean for you. #USCAP2025
Robyn Temple-Smolkin retweeted
At our AMP Middle East meeting in Abu Dhabi, Somak Roy (@roysomak4)will give two presentations, one about what clinical bioinformaticians need to know and one about in silico resources for NGS bioinformatics pipeline validation.
See all speakers: ampmiddleeast25.amp.org/spea…
Robyn Temple-Smolkin retweeted
We're going to be at @TheUSCAP's annual meeting this weekend! Swing by booth 1004 to meet our membership manager, Jocelyn Friedrich; get your hands on some "Molecular in My Pocket" reference cards; and find out what being a member of @AMPath can mean for you. #USCAP2025
Robyn Temple-Smolkin retweeted
🔬 Dive into #bioinformatics challenges with our "Next-Generation Bioinformatics" certificate program! This online training examines complex genomic anomalies in NGS testing. 🌟 Members save 25%! Enroll ➡️ educate.amp.org/local/catalo…
ALT Graphic repeats what is in the post, but it also notes these topics are covered: highly homologous genes, molecular informatics at scale, structural variant discovery, structural variation detection, personalized genomics, and difficult-to-sequence genes and structural variants. It also says you get 6+ hours of lectures, slides, pre- and post-course tests and a certificate of completion from the Association for Molecular Pathology.
Robyn Temple-Smolkin retweeted
We convened a working group to update the guideline for classification, annotation, interpretation and reporting of somatic sequence variants published in 2017. The working group seeks comments on its draft recommendations. Read them and submit a comment: amp.org/clinical-practice/op…
Happy to share I'm now an @ASAEcenter Certified Association Executive (CAE)! Congratulations to all who received their new credential today!
Robyn Temple-Smolkin retweeted
NIST has developed a reference material to support the production of diagnostic tests for the bird flu (H5N1). This nonhazardous genetic material will enhance the nation’s response to outbreaks of disease and ensure companies’ quality control. Read more: nist.gov/news-events/news/20…
ALT A researcher wearing goggles and protective gloves works with a bottle and pipette
Help support @AMPath volunteers working with @AJCCancer to provide #precisionmedicine expertise supporting best practices for #oncology #patientcare? Now there’s a New Year’s resolution I’m happy to keep!
The Association for Molecular Pathology (AMP) has recently joined the @AJCCancer as a new member organization. The AMP advances clinical practice, science, and excellence of molecular and genomic laboratory medicine. Welcome, @AMPath!
Robyn Temple-Smolkin retweeted
Free webinar on Jan. 30: "Germline Testing in Cancer Patients: Molecular Diagnostic Considerations
and Clinical Implications." It'll feature speaker Diana Mandelker of @MSKCancerCenter and provide continuing-education credit: educate.amp.org/local/catalo…
Robyn Temple-Smolkin retweeted
One of the top articles in 2024 in @JMDiagn, AMP's official journal:
⭐DPYD Genotyping Recommendations ⭐
jmdjournal.org/article/S1525…
#openaccess
Robyn Temple-Smolkin retweeted
Not sure what your lab should be doing in light of the FDA's final rule on laboratory-developed testing procedures? We've put together a webpage with a ton of resources to help you at each stage. Check it out and share it with others who need it: amp.org/advocacy/amp-v-fda/f…
Robyn Temple-Smolkin retweeted
.@AMPath is now a member organization of @AJCCancer, which "provides worldwide leadership in the development, promotion and maintenance of evidence-based systems for the classification and management of cancer." facs.org/quality-programs/ca… (cc: @AmColSurgCancer )
Robyn Temple-Smolkin retweeted
#LegacyContent: Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of @AMPath and @Pathologists.
Free in the #OpenArchive: jmdjournal.org/article/S1525…
